Palifermin in the management of mucositis in hematological malignancies: Current evidences and future perspectives

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2009, Pages 305-312

  Niscola, P ^a   Scaramucci, L ^a   Giovannini, M ^a   Ales, M ^a   Bondanini, F ^b   Cupelli, L ^a   Dentamaro, T ^a   Lamanda, M ^c   Natale, G ^a   Palumbo, R ^a   Romani, C ^d   Tendas, A ^a   Tolu, B ^a   Violo, L ^a   De Fabritiis, P ^a  

^a S EUGENIO HOSPITAL   (Italy)

^b SANDRO PERTINI HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

Author keywords

Chemotherapy; Hematopoietic stem cell transplantation; Mucositis; Palifermin; Radiotherapy

Indexed keywords

AMIFOSTINE; BENZYDAMINE; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DOXEPIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; KERATINOCYTE GROWTH FACTOR; LACTOFERRIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PALIFERMIN; PILOCARPINE; PLACEBO; POVIDONE IODINE; REPIFERMIN; SOMATOMEDIN; VELAFERMIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG INHIBITION; EDEMA; ERYTHEMA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEALING; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; MEDLINE; MOUTH HYGIENE; MUCOSA INFLAMMATION; NONHUMAN; PATHOLOGY; REVIEW; SIDE EFFECT; TOOTH DISCOLORATION; TOTAL PARENTERAL NUTRITION; TREATMENT INDICATION; TREATMENT OUTCOME; WHEY; BLOOD DISEASE;

ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTOR 7; HEMATOLOGIC NEOPLASMS; HUMANS; MUCOSITIS;

EID: 74049164226     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789541873     Document Type: Review

References (90)

1. Blijlevens, N.; Donnelly, J.P.; De Pauw, B.E. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant., 2000, 25, 1269.
2. Niscola, P.; Romani, C.; Cupelli, L.; Scaramucci, L.; Tendas, A.; Dentamaro, T.; Amadori, S.; de Fabritiis, P. Mucositis in patients with hematologic malignancies: an overview. Haematologica., 2007, 92(2), 222.
3. Matteucci, P.; Carlo-Stella, C.; Di Nicola, M.; Magni, M.; Guidetti, A.; Marchesi, M.; Gianni, A.M. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Haematologica., 2006, 91(2), 255.
4. Kaplan, J.R.; Wolf, J.S., Jr. Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis. J. Urol., 2009, 181(2), 641.
5. Sonis, S.T. The pathobiology of mucositis. Nat. Rev., 2004, 30, 277.
6. Keefe, D.M. Intestinal mucositis: mechanisms and management. Curr. Opin. Oncol., 2007, 19(4), 323.
7. Bellm, L.A.; Epstein, J.B.; Rose-Ped, A.; Martin, P.; Fuchs, H.J. Patient reports of complications of bone marrow transplantation. Support. Care Cancer, 2000, 8(1), 33.
8. Niscola, P.; Arcuri, E.; Giovannini, M.; Scaramucci, L.; Romani, C.; Palombi, F.; Trapè, G.; Morabito, F. Pain syndromes in haematological malignancies: an overview. Hematol. J., 2004, 5(4), 293.
9. Niscola, P.; Romani, C.; Cartoni, C.; Cupelli, L.; Piccioni, D.; Dentamaro, T.; Tendas, A.; Giovannini, M.; Scaramucci, L.; Tolu, B.; Perrotti, A.P.; de Fabritiis, P. Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk. Res., 2008, 32(1), 197.
10. Niscola, P.; Romani, C.; Scaramucci, L.; Dentamaro, T.; Cupelli, L.; Tendas, A.; Piccioni, D.; Giovannini, M.; Tolu, B.; Cartoni, C.; Arcuri, E.; Perrotti, A.; Palumbo, R.; de Fabritiis, P. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant., 2008, 41(9), 757.
11. O'Brien, S.N.; Blijlevens, N.; Mahfouz, T.H.; Anaissie, E.J. Infections in patients with hematological cancer: recent developments. Hematology (Am. Soc. Hematol. Educ. Program), 2003, 438-72.
12. Blijlevens, N. Cytotoxic treatment-induced gastrointestinal symptoms. Curr. Opin. Support Palliat Care, 2007, 1(1), 16.
13. Brown, C.G.; Wingard, J. Clinical consequences of oral mucositis. Semin. Oncol. Nurs., 2004, 20, 16.
14. Sonis, S.T.; Elting, L.S.; Keefe, D.; Peterson, D.E.; Schubert, M.; Hauer-Jensen, M.; Bekele, B.N.; Raber-Durlacher, J.; Donnelly, J.P.; Rubenstein, E.B. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 2004, 100 (9Suppl.), 1995.
15. Sonis, S.T.; Oster, G.; Fuchs, H.; Bellm, L.; Bradford, W.Z.; Edelsberg, J.; Hayden, V.; Eilers, J.; Epstein, J.B.; LeVeque, F.G.; Miller, C.; Peterson, D.E.; Schubert, M.M.; Spijkervet, F.K.; Horowitz, M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J. Clin. Oncol., 2001, 19(8), 2201.
16. Quinn, B.; Potting, C.M.; Stone, R.; Blijlevens, N.; Fliedner, M.; Margulies, A.; Sharp, L. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur. J. Cancer, 2008, 44(1), 61.
17. No authors listed. WCCNR. Assessing stomatitis: refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can. Oncol. Nurs. J., 1998, 8, 160.
18. McGuire, D.B.; Peterson, D.E.; Muller, S.; Owen, D.C.; Slemmons, M.F.; Schubert, M.M. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest., 2002, 20, 893.
19. Ozturk, M.; Komurcu, S.; Kilic, S.; Ozet, A.; Arpaci, F.; Ozturk, B.; Kuzhan,O.; Ataergin, S. Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Support. Care Cancer, 2009 Feb 6. [Epub ahead of print]
20. Hänel, M.; Kröger, N.; Sonnenberg, S.; Bornhäuser, M.; Krüger, W.; Kroschinsky, F.; Hänel, A.; Metzner, B.; Birkmann, J.; Schmid, B.; Hoffknecht, M.M.; Fiedler, F.; Ehninger, G.; Zander, A.R. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann. Hematol., 2002, 81(2), 96.
21. Blijlevens, N.; Schwenkglenks, M.; Bacon, P.; D'Addio, A.; Einsele, H.; Maertens, J.; Niederwieser, D.; Rabitsch, W.; Roosaar, A.; Ruutu, T.; Schouten, H.; Stone, R.; Vokurka, S.; Quinn, B.; McCann, S.; European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J. Clin. Oncol., 2008, 26(9), 1519.
22. Niscola, P.; Scaramucci, L.; Romani, C.; Cupelli, L.; Tendas, A.; Dentamaro,T.; Ales, M.; Giovannini, M.; Piccioni, D.; Siniscalchi, A.; Tolu, B.; Perrotti, A.; Keefe, D.; de Fabritiis, P. Mucositis in the treatment of haematological malignancies. Ann. Oncol., 2008, 19(Suppl. 7), vii141-5.
23. Weiser, M.A.; O'Brien, S.; Thomas, D.A.; Pierce, S.A.; Lam, T.P.; Kantarjian, H.M. Comparison of two different schedules of granulocyte-colony- stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer, 2002, 94(2), 285.
24. Hueber, A.J.; Leipe, J.; Roesler, W.; Kalden, J.R.; Kallert, S.; Rech, J. Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis. Haematologica, 2006, 91(8Suppl.), ECR32.
25. Mead, G.M.; Sydes, M.R.; Walewski, J.; Grigg, A.; Hatton, C.S.; Pescosta, N.; Guarnaccia, C.; Lewis, M.S.; McKendrick, J.; Stenning, S.P.; Wright, D. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol., 2002, 13(8), 1264.
26. Schmidt, E.; Thoennissen, N.H.; Rudat, A.; Bieker, R.; Schliemann, C.; Mesters, R.M.; Zühlsdorf. M.; Müller-Tidow, C.; Berdel, W.E. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann. Oncol., 2008, 19(9), 1644.
27. Keefe, D.M.; Schubert, M.M.; Elting, L.S.; Sonis, S.T.; Epstein, J.B.; Raber-Durlacher, J.E.; Migliorati, C.A.; McGuire, D.B.; Hutchins, R.D.; Peterson, D.E. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109(5), 820.
28. Keefe, D.M.; Sonis, S.T.; Bowen, J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin. Emerg. Drugs, 2008, 13(3), 511.
29. Spielberger, R.; Stiff, P.; Bensinger, W.; Gentile, T.; Weisdorf, D.; Kewalramani, T.; Shea, T.; Yanovich, S.; Hansen, K.; Noga, S.; McCarty, J.; LeMaistre, C.F.; Sung, E.C.; Blazar, B.R.; Elhardt, D.; Chen, M.G.; Emmanouilides, C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 2004, 351(25), 2590.
30. Stiff ,P.J.; Emmanouilides, C.; Bensinger, W.I.; Gentile, T.; Blazar, B.; Shea, T.C.; Lu, J.; Isitt, J.; Cesano, A.; Spielberger, R. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol., 2006, 24(33), 5186.
31. Rubin, J.S.; Osada, H.; Finch, P.W.; Taylor, W.G.; Rudikoff, S.; Aaronson S.A. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc. Natl. Acad. Sci. USA, 1989, 86(3), 802.
32. Finch, P.W.; Rubin, J.S.; Miki, T.; Ron, D.; Aaronson, S.A. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 1989, 245(4919), 752.
33. Finch, P.W.; Rubin, J.S. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv. Cancer Res., 2004, 91, 69.
34. Braun, S.; Hanselmann, C.; Gassmann, M.G.; auf dem Keller, U.; Born-Berclaz, C.; Chan, K.; Kan, Y.W.; Werner, S. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell Biol., 2002, 22(15), 5492.
35. auf demKeller, U.; Krampert, M.; Kümin, A.; Braun, S.; Werner, S. Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur. J. Cell Biol., 2004, 83(11-12), 607.
36. Blijlevens, N.; Sonis, S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann. Oncol., 2007, 18(5), 817.
37. Hensley, M.L.; Hagerty, K.L.; Kewalramani, T.; Green, D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; Thigpen, J.T.; Trotti, A. 3rd; von Hoff, D.; Schuchter, L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, 27(1), 127.
38. No author listed. European Public Assessment Report EPAR. Kepivance. EPAR summary for the public. [Accessed 23 June 2009] http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ kepivance/ 29841405en1.pdf
39. Ulich, T.R.; Whitcomb, L.; Tang, W.; O'Conner Tressel, P.; Tarpley, J.; Yi, E.S.; Lacey, D. Keratinocyte growth factor ameliorates cyclophosphamide- induced ulcerative hemorrhagic cystitis. Cancer Res., 1997, 57(3), 472.
40. Beaven, A.W.; Shea, T.C. The effect of palifermin on chemotherapy and radiation therapy-induced mucositis: a review of the current literature. Support. Cancer Ther., 2007, 4(4), 188.
41. Johansson, J.E.; Hasséus, B.; Johansson, P.; Eklöf, C.; Ohman, D.; Stockelberg, D. Gut protection by palifermin during autologous haematopoietic SCT. Bone Marrow Transplant., 2008, 43(10), 807.
42. Goldberg, J.; Jacobsohn, D.A.; Zahurak, M.L.; Vogelsang, G.B. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol. Blood Marrow Transplant, 2005, 11, 101.
43. Ross, W.A.; Couriel, D. Colonic graft-versus-host disease. Curr. Opin. Gastroenterol., 2005, 21, 64.
44. Copelan, E.A. Hematopoietic stem-cell transplantation. N. Engl. J. Med., 2006, 354, 1813.
45. Horwitz, M.E. Sullivan KM. Chronic graft-versus-host disease. Blood Rev., 2006, 20, 15.
46. Rzepecki, P.; Sarosiek, T.; Barzal, J.; Oborska, S.; Nurzynski, P.; Wasko, A.; Szczylik, C. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience. J. BUON, 2007, 12(4), 477.
47. Langner, S.; Staber, P.; Schub, N.; Gramatzki, M.; Grothe, W.; Behre, G.; Rabitsch, W.; Urban, C.; Linkesch, W.; Neumeister, P. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant., 2008, 42(4), 275.
48. Ellison, C.A.; Makar, B.M.; Wiseman, J.M.; Gheorghiu, I.; Taniguchi, M.; Gartner, J.G. Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease. J. Clin. Immunol., 2008, 28(5), 600.
49. Kelly, R.M.; Highfill, S.L.; Panoskaltsis-Mortari, A.; Taylor, P.A.; Boyd, R.L.; Holländer, G.A.; Blazar, B.R. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood, 2008, 111(12), 5734.
50. Seggewiss, R.; Loré, K.; Guenaga, F.J.; Pittaluga, S.; Mattapallil, J.; Chow, C.K.; Koup, R.A.; Camphausen, K.; Nason, M.C.; Meier-Schellersheim, M.; Donahue, R.E.; Blazar, B.R.; Dunbar, C.E.; Douek, D.C. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood, 2007, 110(1), 441.
51. Min, D.; Panoskaltsis-Mortari, A.; Kuro, O. M.; Holländer, G.A.; Blazar, B.R.; Weinberg, K.I. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood, 2007, 109(6), 2529.
52. Blazar, B.R.; Weisdorf, D.J.; Defor, T.; Goldman, A.; Braun, T.; Silver, S.; Ferrara, J.L. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood, 2006, 108(9), 3216.
53. Nasilowska-Adamska, B.; Rzepecki, P.; Manko, J.; Czyz, A.; Markiewicz, M.; Federowicz, I.; Tomaszewska, A.; Piatkowska-Jakubas, B.; Wrzesien-Kus, A.; Bieniaszewska, M.; Duda, D.; Szydlo, R.; Halaburda, K.; Szczepinski, A.; Lange, A.; Hellman, A.; Robak, T.; Skotnicki, A.; Jedrzejczak, W.W.; Walewski, J.; Holowiecki, J.; Komarnicki, M.; Dmoszynska, A.; Warzocha, K.; Marianska, B. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant., 2007, 40(10), 983.
54. Levine, J.E.; Blazar, B.R.; DeFor, T.; Ferrara, J.L.; Weisdorf, D.J. Long-term follow-up of a phase I/II randomized, placebocontrolled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol. Blood Marrow Transplant., 2008, 14(9), 1017.
55. van der Velden, W.J.; Herbers, A.H.; Blijlevens, N.M. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant., 2009, 43(1), 85.
56. Hassan, Z.; Remberger, M.; Svenberg, P.; Elbander, M.; Omazic, B.; Mattsson, J.; Conrad, R.;Svahn, B.M.; Ahlgren, A.; Sairafi, D.; Aschan, J.; Le Blanc, K.; Barkholt, L.; Ringdén, O. Hemorrhagic cystitis: a retrospective single-center survey. Clin. Transplant., 2007, 21(5), 659.
57. Lee, G.W.; Lee, J.H.; Choi, S.J.; Kim, S.; Seol, M.; Kim, W.K.; Lee, J.S.; Lee, K.H. Hemorrhagic cystitis following allogeneic hematopoietic cell transplantation. J. Korean Med. Sci., 2003, 18(2), 191.
58. Jaal, J.; Dörr, W. Effect of recombinant human keratinocyte growth factor (rHuKGF, Palifermin) on radiation-induced mouse urinary bladder dysfunction. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69(2), 528.
59. Czibere, A.; Bruns, I.; Graef, T.; Fenk, R.; Zohren, F.; Safaian, N.; Mueller, M.; Haas, R.; Kobbe, G. Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor. Biol. Blood Marrow Transplant., 2007, 13(7), 872.
60. Barasch, A.; Elad, S.; Altman, A.; Damato, K.; Epstein, J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer, 2006, 14(6), 528.
61. Worthington, H.V.; Clarkson, J.E.; Eden, O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev., 2007, (4), CD000978.
62. Richards, D. Prevention of oral mucositis in cancer patients treated with chemotherapy or radiotherapy. Evid. Based Dent., 2006, 7(4), 106.
63. von Bültzingslöwen, I.; Brennan, M.T.; Spijkervet, F.K.; Logan, R.; Stringer, A.; Raber-Durlacher, J.E.; Keefe, D. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer, 2006, 14(6), 519.
64. Hofmeister, C.C.; Stiff, P.J. Mucosal protection by cytokines. Curr. Hematol. Rep., 2005, 4, 446.
65. Hejna, M.; Köstler, W.J.; Raderer, M.; Steger, G.G.; Brodowicz, T.; Scheithauer, W.; Wiltschke, C.; Zielinski, C.C. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur. J. Cancer, 2001, 37(16), 1994.
66. Ryu, J.K.; Swann, S.; LeVeque, F.; Scarantino, C.W.; Johnson, D.; Chen, A.; Fortin, A.; Pollock, J.; Kim, H.; Ang, K.K. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67(3), 643.
67. Fung, S.M.; Ferrill, M.J. Granulocyte macrophage-colony stimulating factor and oral mucositis. Ann. Pharmacother., 2002, 36(3), 517.
68. Migliorati, C.A.; Oberle-Edwards, L.; Schubert, M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support. Care Cancer, 2006, 14, 533.
69. Lövenich, H.; Schütt-Gerowitt, H.; Keulertz, C.; Waldschmidt, D.; Bethe, U.; Söhngen, D.; Cornely, O.A. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplant., 2005, 35(10), 997.
70. Potting, C.M.; Uitterhoeve, R.; Op Reimer, W.S.; Van Achterberg, T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur. J. Cancer Care (Engl.), 2006, 15(5), 431.
71. Vokurka, S.; Bystrická, E.; Koza, V.; Scudlová, J.; Pavlicová, V.; Valentová, D.; Bocková, J.; Misaniová, L. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT - results of a randomized multicentre study. Support. Care Cancer, 2005, 13(7), 554.
72. Lockhart, P.B.; Brennan, M.T.; Kent, M.L.; Packman, C.H.; Norton, H.J.; Fox, P.C.; Frenette, G. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant., 2005, 35(7), 713.
73. Elad, S.; Ackerstein, A.; Bitan, M.; Shapira, M.Y.; Resnick, I.; Gesundheit, B.; Cohen, Y.; Diss, O.; Barak, D.; Dray, L.; Or, R. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant., 2006, 37(8), 757.
74. Sironi, M.; Milanese, C.; Vecchi, A.; Polenzani, L.; Guglielmotti, A.; Coletta, I., Landolfi, C.; Soldo, L.; Mantovani, A.; Pinza, M. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int. J. Clin. Lab. Res., 1997, 27(2), 118.
75. Yuen, K.Y.; Woo, P.C.; Tai, J.W.; Lie, A.K.; Luk, J.; Liang, R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica, 2001, 86, 554.
76. Capelli, D.; Santini, G.; De Souza, C.; Poloni, A.; Marino, G.; Montanari, M.; Lucesole, M.; Brunori, M.; Massidda, D.; Offidani, M.; Leoni, P.; Olivieri, A. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br. J. Haematol., 2000, 110(2), 300.
77. Crowther, M.; Avenell, A.; Culligan, D.J. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant, 2009, Mar 9. [Epub ahead of print].
78. Lalla, R.V.; Schubert, M.M.; Bensadoun, R.J.; Keefe, D. Anti-inflammatory agents in the management of alimentary mucositis. Support. Care Cancer, 2006, 14, 558.
79. Epstein, J.B.; Schubert, M.M. Managing pain in mucositis. Semin. Oncol. Nurs., 2004, 20, 30.
80. Cerchietti, L.C.; Navigante, A.H.; Körte, M.W.; Cohen, A.M.; Quiroga, P.N.; Villaamil, E.C.; Bonomi, M.R.; Roth, B.M. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain, 2003, 105(1-2), 265.
81. Epstein, J.B.; Epstein, J.D.; Epstein, M.S.; Oien, H.; Truelove, E.L. Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth. Analg., 2006, 103(2), 465.
82. Epstein, J.B.; Epstein, J.D.; Epstein, M.S.; Oien, H.; Truelove, E.L. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. Spec. Care Dentist., 2008, 28(2), 73.
83. Chapman, C.R.; Donaldson, G.W.; Jacobson, R.C.; Hautman, B. Differences among patients in opioid self-administration during bone marrow transplantation. Pain, 1997, 71, 213.
84. Strupp, C.; Sudhoff, T.; Germing, U.; Hunerliturkoglu, A.; Schneider, P.; Niederste-Hollenberg, A.; Heyll, A.; Aul, C. Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol. Rep. 2000, 7, 659.
85. Demarosi, F.; Lodi, G.; Soligo, D.; Sardella, A.; Volpe, A.D.; Carrassi, A.; Deliliers, G.L. Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant., 2004, 33(12), 1247.
86. Kim, J.G.; Sohn, S.K.; Kim, D.H.; Baek, J.H.; Chae, Y.S.; Bae, N.Y.; Kim, S.Y.; Lee, K.B. Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. Transplant. Proc., 2005, 37(10), 4488.
87. Elting, L.S.; Shih, Y.C.; Stiff, P.J.; Bensinger, W.; Cantor, S.B., Cooksley, C., Spielberger, R.; Emmanoulides, C. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol. Blood Marrow Transplant., 2007, 13(7), 806.
88. Zia-Amirhosseini, P.; Hurd, D.D.; Salfi, M.; Cheah, T.C.; Aycock, J.; Cesano, A. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy, 2007, 27(10), 1353.
89. Gillespie, B.; Zia-Amirhosseini, P.; Salfi, M.; Kakkar, T.; Wang, J.; Gupta, S.; Smith, B.; Robson, R., Sullivan, J.T. Effect of renal function on the pharmacokinetics of palifermin. J. Clin. Pharmacol., 2006, 46(12), 1460.
90. Verhagen, M.P.; Wondergem, M.J.; Visser, O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant., 2009, 43(8), 665.